SPN-804O

Supernus Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	SPN-804O
Also known as	oxcarbazepine extended-release, OXC XR, Oxtellar XR
Sponsor	Supernus Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients (PHASE1)
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SPN-804O CI brief — competitive landscape report
SPN-804O updates RSS · CI watch RSS
Supernus Pharmaceuticals, Inc. portfolio CI